ClinicalTrials.gg
CompletedNCT06203457Rho plusUpdated Feb 20, 2026Results posted

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

A Phase 2 interventional study of Efgartigimod in Primary Sjögren's Syndrome, sponsored by argenx. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by argenx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Efgartigimod has the potential to improve disease manifestations by the reduction of IgG autoantibodies in Sjogren's Syndrome (SjD or pSS). This open-label extension study will evaluate the long-term safety of efgartigimod in participants with SjD who have completed the treatment period of the qualifying efgartigimod study (ARGX-113-2106).

02

Conditions studied

  • Primary Sjögren's Syndrome
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least the legal age of consent for clinical trials when signing the ICF
  • Is capable of providing signed and complying with protocol requirements
  • Agrees to use measures consistent with local regulations and the following: must have a negative urine pregnancy test at baseline before receiving IMP
  • Has completed the qualifying efgartigimod SjD studies and agrees to continue study drug treatment without interruption in the extension study

Exclusion criteria

Exclusion Criteria:

  • disease (including newly diagnosed or cardiovascular disease) or intention to have surgery during the study; or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
  • Pregnant or intention to become pregnant during the study
  • Any severe systemic SjD manifestation that may put the participant at undue risk based on the investigator's opinion
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Efgartigimod

    All participants received efgartigimod 10 mg/kg via intravenous infusion once weekly or once every 2 weeks for up to 48 weeks in this study.

    Biological: Efgartigimod

Interventions

  • BiologicalEfgartigimod

    Patients receiving efgartigimod infusions

06

What researchers measure

Primary outcomes

  1. Number of Participants With TEAEs, TESAEs and TEAESIs

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration. Adverse events in the 'Infections and infestations' SOC were defined as AE of Special Interest (AESIs) because efgartigimod causes a transient reduction in total IgG levels.

    Time frame: From the first dose of study drug (Day 1) up to 60 days post last study drug, approximately 56 weeks

Secondary outcomes

  1. Number of CRESS Responders at Weeks 24 and 48

    A composite of relevant endpoints for Sjögren's syndrome (CRESS) measures systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function, and serology, developed to assess treatment efficacy in participants with SjD. A responder is defined as improvement in at least 3 of the above mentioned 5 items of CRESS. The score ranges from 0 to 9 (higher score = worse symptoms). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Weeks 24 and 48

  2. Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48

    European alliance of associations for rheumatology (EULAR) SjD activity index (ESSDAI) measures systemic disease activity in 12 domains. The activity levels of each domain are multiplied by their respective weights to obtain the total score between 0 and 123 (higher score = worse symptoms). Minimally clinically important improvement in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  3. Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48

    ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Weeks 24 and 48

  4. Number of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48

    Clinical EULAR Sjögren's syndrome disease activity index (clinESSDAI) includes same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have biological domain.This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. clinESSDAI score ranges between 0-135 (higher score=worse symptoms).Minimal clinically important improvement in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Weeks 24 and 48.Baseline=last available non-missing measurement from parent study ARGX-113-2106.Responder rates for efgartigimod-efgartigimod group in follow-up study are supplemental to those in antecedent study (ARGX-113-2106).Because responders from ARGX-113-2106 study (mainly in efgartigimod-efgartigimod group) potentially started ARGX-113-2211 with lower baseline scores,further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  5. Number of Participants With Low Disease Activity in clinESSDAI at Weeks 24 and 48

    clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Weeks 24 and 48

  6. Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSPRI at Weeks 24 and 48

    EULAR Sjögren's syndrome patient-reported index (ESSPRI) is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. The total global score ranges from 0 to 10 by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least \>=15% at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this measure is inherently challenging due to biological and clinical limitations.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  7. Change From Baseline in ESSDAI Score at Weeks 24 and 48

    ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains: 11 organ-specific domains (cutaneous, pulmonary, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, and lymphadenopathic) and 1 biological domain reflecting B-cell activity that contributes to disease activity level scoring. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  8. Change From Baseline in clinESSDAI Score at Weeks 24 and 48

    clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  9. Change From Baseline in ESSPRI Score at Weeks 24 and 48

    ESSPRI is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. Each item includes a numeric rating scale ranging from 0: no symptoms (dryness, fatigue, or pain) to 10: maximal imaginable (dryness, fatigue, or pain). The total global score ranges from 0 to 10 and the ESSPRI is calculated by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

    Time frame: Baseline (Day 1) and Weeks 24 and 48

  10. Number of STAR Responders at Weeks 24 and 48

    Sjögren's tool for assessing response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a participant with a score of at least 5 points. Due to the weighting, participant must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

    Time frame: Weeks 24 and 48

  11. Percent Change From Baseline in Total IgG Levels in Serum at Week 48

    Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum. Total IgG concentrations were quantified using validated methods at a diagnostical laboratory. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

    Time frame: Baseline (Day 1) and Week 48

  12. Percent Change From Baseline in Autoantibodies in Serum at Week 48

    Blood samples were collected at indicated timepoints to assess serum autoantibodies: anti-Ro/Sjögren's syndrome-related antigen A (SS-A) and anti-La/Sjögren's syndrome-related antigen B (SS-B). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

    Time frame: Baseline (Day 1) and Week 48

  13. Serum Concentrations of Efgartigimod

    Serum samples were collected at indicated timepoints to assess the pharmacokinetic (PK) profile of efgartigimod.

    Time frame: Pre-dose and post-dose at Baseline (Day 1) and pre-dose at Weeks 24 and 48

  14. Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period

    Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Samples were analyzed by the designated laboratory in a 3-tiered approach using validated immunogenicity assays. ADA incidence included total number of participants with treatment-boosted and treatment-induced ADA. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Number of participants with ADA incidence is presented here.

    Time frame: From Baseline (Day 1) up to 48 weeks

07

Results

Posted Feb 20, 2026

Participant flow

This open-label, multicenter extension study was conducted at 11 sites in Belgium, Hungary, and Poland in adult participants with Sjögren's disease (SjD) who completed parent efgartigimod study ARGX-113-2106 (NCT05817669).

Participant flow — Overall Study
MilestoneEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Started177
Completed123
Not completed54
Withdrew: Withdrawal by subject11
Withdrew: Adverse event12
Withdrew: Lack of efficacy10
Withdrew: Protocol violation11
Withdrew: Personal reason10

Outcome measures

PrimaryNumber of Participants With TEAEs, TESAEs and TEAESIs

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. Treatment-emergent adverse events (TEAEs) were defined as AEs with onset on or after the first administration of study drug up to and including 60 days after the last study drug administration. Adverse events in the 'Infections and infestations' SOC were defined as AE of Special Interest (AESIs) because efgartigimod causes a transient reduction in total IgG levels.

Time frame:
From the first dose of study drug (Day 1) up to 60 days post last study drug, approximately 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs, TESAEs and TEAESIs
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
TEAEs156
TESAEs02
TEAESIs105
SecondaryNumber of CRESS Responders at Weeks 24 and 48

A composite of relevant endpoints for Sjögren's syndrome (CRESS) measures systemic disease activity, patient-reported symptoms, tear gland function, salivary gland function, and serology, developed to assess treatment efficacy in participants with SjD. A responder is defined as improvement in at least 3 of the above mentioned 5 items of CRESS. The score ranges from 0 to 9 (higher score = worse symptoms). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of CRESS Responders at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 241 (0.30 to 25.01)4 (22.53 to 87.12)
Week 482 (2.13 to 32.62)2 (5.34 to 65.87)
SecondaryNumber of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48

European alliance of associations for rheumatology (EULAR) SjD activity index (ESSDAI) measures systemic disease activity in 12 domains. The activity levels of each domain are multiplied by their respective weights to obtain the total score between 0 and 123 (higher score = worse symptoms). Minimally clinically important improvement in ESSDAI was defined as improvement of at least 3 points in ESSDAI score at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSDAI at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 243 (4.99 to 39.56)2 (5.34 to 65.87)
Week 481 (0.30 to 25.01)2 (5.34 to 65.87)
SecondaryNumber of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48

ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Low disease activity in ESSDAI was defined as ESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Low Disease Activity in ESSDAI at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 249 (31.08 to 73.99)4 (22.53 to 87.12)
Week 487 (21.19 to 63.60)3 (12.88 to 77.47)
SecondaryNumber of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48

Clinical EULAR Sjögren's syndrome disease activity index (clinESSDAI) includes same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have biological domain.This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. clinESSDAI score ranges between 0-135 (higher score=worse symptoms).Minimal clinically important improvement in clinESSDAI was defined as improvement of at least 3 points in clinESSDAI score at Weeks 24 and 48.Baseline=last available non-missing measurement from parent study ARGX-113-2106.Responder rates for efgartigimod-efgartigimod group in follow-up study are supplemental to those in antecedent study (ARGX-113-2106).Because responders from ARGX-113-2106 study (mainly in efgartigimod-efgartigimod group) potentially started ARGX-113-2211 with lower baseline scores,further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Minimal Clinically Important Improvement From Baseline in clinESSDAI at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 242 (2.13 to 32.62)2 (5.34 to 65.87)
Week 481 (0.30 to 25.01)2 (5.34 to 65.87)
SecondaryNumber of Participants With Low Disease Activity in clinESSDAI at Weeks 24 and 48

clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Low disease activity in clinESSDAI was defined as clinESSDAI score of less than 5 at Weeks 24 and 48. Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Low Disease Activity in clinESSDAI at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 249 (31.08 to 73.99)4 (22.53 to 87.12)
Week 487 (21.19 to 63.60)3 (12.88 to 77.47)
SecondaryNumber of Participants With Minimal Clinically Important Improvement From Baseline in ESSPRI at Weeks 24 and 48

EULAR Sjögren's syndrome patient-reported index (ESSPRI) is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. The total global score ranges from 0 to 10 by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Minimal clinically important improvement in ESSPRI was defined as decrease of 1 point or at least \>=15% at Weeks 24 and 48. Baseline was defined as the last available non-missing measurement from the study ARGX-113-2106. Responder rates for the efg-efg group in the follow-up study are supplemental to those in the ARGX-113-2106 study. Because responders from the ARGX-113-2106 study (mainly in the efg-efg group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this measure is inherently challenging due to biological and clinical limitations.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Minimal Clinically Important Improvement From Baseline in ESSPRI at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 244 (8.46 to 46.05)1 (0.73 to 52.07)
Week 484 (8.46 to 46.05)2 (5.34 to 65.87)
SecondaryChange From Baseline in ESSDAI Score at Weeks 24 and 48

ESSDAI measures systemic disease activity in participants with SjD and consists of 12 domains: 11 organ-specific domains (cutaneous, pulmonary, renal, articular, muscular, peripheral nervous system, central nervous system, hematological, glandular, constitutional, and lymphadenopathic) and 1 biological domain reflecting B-cell activity that contributes to disease activity level scoring. The activity levels of each domain (range: 0-3 points) are multiplied by their respective weights (range: 1-6 points) to obtain the total score between 0 and 123 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · score on a scale
Change From Baseline in ESSDAI Score at Weeks 24 and 48
score on a scaleEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 240.000 (-9 to 6)-3.000 (-5 to 0)
Week 48-1.500 (-9 to 4)-4.000 (-5 to 2)
SecondaryChange From Baseline in clinESSDAI Score at Weeks 24 and 48

clinESSDAI includes the same 11 organ-specific domains as ESSDAI but with different domain weighting and this scale does not have the biological domain. This way any change in clinESSDAI score reflects disease specific features irrespective of B-cell activity. The clinESSDAI score ranges between 0-135 (higher score = worse symptoms). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · score on a scale
Change From Baseline in clinESSDAI Score at Weeks 24 and 48
score on a scaleEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 240.000 (-11 to 4)-3.000 (-6 to 0)
Week 48-0.500 (-11 to 4)-4.000 (-6 to 4)
SecondaryChange From Baseline in ESSPRI Score at Weeks 24 and 48

ESSPRI is a questionnaire developed to measure self-reported symptoms in participants with SjD and consists of 3 items that measure dryness, fatigue, and pain. Each item includes a numeric rating scale ranging from 0: no symptoms (dryness, fatigue, or pain) to 10: maximal imaginable (dryness, fatigue, or pain). The total global score ranges from 0 to 10 and the ESSPRI is calculated by averaging the numeric scores for pain, fatigue, and dryness, with higher scores indicating more symptoms. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

Time frame:
Baseline (Day 1) and Weeks 24 and 48
Reported as:
Median · score on a scale
Change From Baseline in ESSPRI Score at Weeks 24 and 48
score on a scaleEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 240.000 (-2.00 to 0.67)0.167 (-5.00 to 1.00)
Week 480.333 (-3.33 to 2.00)-2.000 (-5.00 to 0.00)
SecondaryNumber of STAR Responders at Weeks 24 and 48

Sjögren's tool for assessing response (STAR) is a composite endpoint assessing multiple clinically relevant disease features. A STAR responder is defined as a participant with a score of at least 5 points. Due to the weighting, participant must be a responder on either systemic disease activity (ESSDAI), patient-reported symptoms (ESSPRI), or both to be an overall STAR responder. The score ranges between 0 and 9 (higher score = worse outcome). Responder rates for the efgartigimod-efgartigimod group in the follow-up study are supplemental to those in the antecedent study (ARGX-113-2106). Because responders from the ARGX-113-2106 study (mainly in the efgartigimod-efgartigimod group) potentially started the ARGX-113-2211 with lower baseline scores, further improvement on this efficacy measure is inherently challenging due to clinical and biological limitations.

Time frame:
Weeks 24 and 48
Reported as:
Count of participants · Participants
Number of STAR Responders at Weeks 24 and 48
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Week 241 (0.30 to 25.01)2 (5.34 to 65.87)
Week 482 (2.13 to 32.62)3 (12.88 to 77.47)
SecondaryPercent Change From Baseline in Total IgG Levels in Serum at Week 48

Blood samples were collected at indicated timepoints to assess the total Immunoglobulin (Ig)G levels in serum. Total IgG concentrations were quantified using validated methods at a diagnostical laboratory. Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Total IgG Levels in Serum at Week 48
percent changeEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Percent Change From Baseline in Total IgG Levels in Serum at Week 4836.266 ± 24.1776-37.800 ± 12.5728
SecondaryPercent Change From Baseline in Autoantibodies in Serum at Week 48

Blood samples were collected at indicated timepoints to assess serum autoantibodies: anti-Ro/Sjögren's syndrome-related antigen A (SS-A) and anti-La/Sjögren's syndrome-related antigen B (SS-B). Baseline was defined as the last available non-missing measurement from the parent study ARGX-113-2106.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Autoantibodies in Serum at Week 48
percent changeEfgartigimod-EfgartigimodPlacebo-Efgartigimod
SS-A Antibody-1.227 ± 4.2512-14.646 ± 25.3673
SS-B Antibody82.487 ± 122.72630.000 ± 0.0000
SecondarySerum Concentrations of Efgartigimod

Serum samples were collected at indicated timepoints to assess the pharmacokinetic (PK) profile of efgartigimod.

Time frame:
Pre-dose and post-dose at Baseline (Day 1) and pre-dose at Weeks 24 and 48
Reported as:
Mean · microgram/milliliter (mcg/mL)
Serum Concentrations of Efgartigimod
microgram/milliliter (mcg/mL)Efgartigimod-EfgartigimodPlacebo-Efgartigimod
Baseline, pre-dose14.74 ± 4.845—
Baseline, post-dose213.3 ± 55.19215.9 ± 29.40
Week 24, pre-dose4.428 ± 5.1351.558 ± 0.2147
Week 48, pre-dose5.725 ± 6.235NA ± NA
SecondaryNumber of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period

Blood samples were collected to assess anti-drug antibodies (ADAs) against efgartigimod. Samples were analyzed by the designated laboratory in a 3-tiered approach using validated immunogenicity assays. ADA incidence included total number of participants with treatment-boosted and treatment-induced ADA. Treatment-boosted ADA was defined as participants who had a baseline positive sample and the titer value increased 4-fold or more compared to baseline. Treatment-induced ADA was defined as participants who had a baseline negative sample and at least 1 positive post-baseline samples. Number of participants with ADA incidence is presented here.

Time frame:
From Baseline (Day 1) up to 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period
ParticipantsEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period64

Adverse events

Collected over From the first dose of study drug (Day 1) up to 60 days post last study drug, approximately 56 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod-Efgartigimod0/17 (0%)0/17 (0%)15/17 (88.2%)
Placebo-Efgartigimod0/7 (0%)2/7 (28.6%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Infusion related reactionInjury, poisoning and procedural complications0/172/7
Most frequent other events
Showing 10 of 76
Most frequent other events
EventEfgartigimod-EfgartigimodPlacebo-Efgartigimod
Upper respiratory tract infectionInfections and infestations1/173/7
BronchitisInfections and infestations0/172/7
ConjunctivitisInfections and infestations2/172/7
Oral herpesInfections and infestations1/172/7
NasopharyngitisInfections and infestations4/170/7
COVID-19Infections and infestations3/170/7
CystitisInfections and infestations3/171/7
HeadacheNervous system disorders3/171/7
Gastric antral vascular ectasiaGastrointestinal disorders0/171/7
ToothacheGastrointestinal disorders0/171/7

Baseline characteristics

Analysis was performed on full analysis set (FAS) which included all enrolled participants.

Age, Continuous
Age, Continuous(years)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Mean51.2 ± 13.0951.3 ± 11.4851.2 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Female16723
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
Hispanic or Latino000
Not Hispanic or Latino17724
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efgartigimod-EfgartigimodPlacebo-EfgartigimodTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White17724
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Vita Verum Medical Egeszsegugyi Szolgaltato Bt.
    Székesfehérvár, 8000, Hungary
  • MCBK SC
    Grodzisk Mazowiecki, 05 825, Poland
  • Centrum Medyczne Plejady
    Krakow, 30 363, Poland
  • Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.
    Poznan, 60-848, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, 60 185, Poland
  • MICS Centrum Medyczne Warszawa
    Warsaw, 00 874, Poland
  • Klinika Reuma Park Sp zoo Sp K
    Warsaw, 02 665, Poland
  • Narodowy Instytut Geriatrii
    Warsaw, 02637, Poland
  • FutureMeds sp zoo
    Wroclaw, 50 088, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

Results were first posted in Feb 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Jan 12, 2024
StartActual
Nov 29, 2023
Primary completionActual
Feb 3, 2025
CompletionActual
Feb 3, 2025
Results first posted
Feb 20, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06203457
Lead sponsor
argenx
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Nov 29, 2023
Primary completion
Feb 3, 2025
Completion
Feb 3, 2025
Results posted
Feb 20, 2026
Last update
Feb 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion